Pharmaceutical Grade CAS 1092939-17-7 Ruxolitinib Phosphate 99% Assay Ruxolitinib Phosphate Anti Cancer Ruxolitinib Phosphate

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Ruxolitinib Phosphate
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Product Name: Ruxolitinib Phosphate
• Name: Ruxolitinib Phosphate Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 1092939-17-7
• Mf: C17h21n6o4p
• MW: 404.37
• Melting Point: 186-190
• Density: 1.40
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 1000kg/Month

Product Description

Pharmaceutical Grade CAS 1092939-17-7 Ruxolitinib Phosphate 99% Assay Ruxolitinib Phosphate Anti Cancer Ruxolitinib Phosphate

Product Description

Product Details

Product Name	Ruxolitinib
CAS No.	1092939-17-7
Purity	99%
MW	306.36500
Appearance and shape	White to off-white powder

Ruxolitinib is the first oral medication that used for the treatment of myelofibrosis. It is a small-molecule inhibitor of the tyrosine kinase (namely, JAK1 and JAK2) and is suitable for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia Vera myelofibrosis and post essential thrombocythemia myelofibrosis.

Application&Function

Function of Ruxolitinib
1.It is used to treat myelofibrosis.
2.It is used to treat polycythemia vera.
Application of Ruxolitinib
1.Myelofibrosis (a bone marrow disease) that is intermediate or high-risk.
2. Primary myelofibrosis.
3.Post-polycythemia vera myelofibrosis.
4.Post-essential thrombocythemia myelofibrosis.

Specification